Akt inhibitor MK-2206 in combination with Bendamustine and Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results from the N1087 Alliance Study

Akt is a downstream target of B cell receptor signaling and is a central regulator of CLL cell survival. We aim to investigate the safety and efficacy of the Akt inhibitor MK-2206 in combination with bendamustine and rituximab (BR) in relapsed and/or refractory CLL in a phase I/II study. A standard...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Am J Hematol
Prif Awduron: Larsen, Jeremy T., Shanafelt, Tait D., Leis, Jose F., LaPlant, Betsy, Call, Tim, Pettinger, Adam, Hanson, Curtis, Erlichman, Charles, Habermann, Thomas Matthew, Reeder, Craig, Nikcevich, Daniel, Bowen, Deborah, Conte, Michael, Boysen, Justin, Secreto, Charla, Lesnick, Connie, Tschumper, Renee, Jelinek, Diane, Kay, Neil E., Ding, Wei
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2017
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5507724/
https://ncbi.nlm.nih.gov/pubmed/28402581
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.24762
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg